Cargando…
Cost-Effectiveness of iGlarLixi in People with Type 2 Diabetes Mellitus Suboptimally Controlled on Basal Insulin Plus Metformin in the UK
INTRODUCTION: A cost-effectiveness analysis was conducted comparing a fixed-ratio combination (FRC) of insulin glargine 100 units/mL plus lixisenatide (iGlarLixi) versus the FRC of insulin degludec plus liraglutide (iDegLira) and the free-combination comparators insulin glargine plus dulaglutide (iG...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8586275/ https://www.ncbi.nlm.nih.gov/pubmed/34714523 http://dx.doi.org/10.1007/s13300-021-01159-y |
_version_ | 1784597861506220032 |
---|---|
author | McCrimmon, Rory J. Falla, Edel Sha, Jo Zhou Alsaleh, Abdul Jabbar Omar Lew, Elisheva Hudson, Richard Baxter, Mike Palmer, Karen |
author_facet | McCrimmon, Rory J. Falla, Edel Sha, Jo Zhou Alsaleh, Abdul Jabbar Omar Lew, Elisheva Hudson, Richard Baxter, Mike Palmer, Karen |
author_sort | McCrimmon, Rory J. |
collection | PubMed |
description | INTRODUCTION: A cost-effectiveness analysis was conducted comparing a fixed-ratio combination (FRC) of insulin glargine 100 units/mL plus lixisenatide (iGlarLixi) versus the FRC of insulin degludec plus liraglutide (iDegLira) and the free-combination comparators insulin glargine plus dulaglutide (iGlar plus Dula) and basal insulin plus liraglutide (BI plus Lira). METHODS: The IQVIA Core Diabetes Model was used to estimate lifetime costs and outcomes for a cohort of patients with type 2 diabetes mellitus (T2DM) from the UK healthcare perspective. Initial clinical data for iGlarLixi were based on the randomized, controlled LixiLan-L trial and the relative treatment effects for comparators were based on an indirect treatment comparison using data from the AWARD-9 (iGlar plus Dula), LIRA ADD2 BASAL (BI plus Lira), and DUAL V (iDegLira) trials. Costs were derived from publicly available sources. Lifetime costs (in British Pound Sterling [£]) and quality-adjusted life-years (QALYs) were predicted; net monetary benefit (NMB) for iGlarLixi versus comparators was derived using a willingness-to-pay threshold of £20,000. Extensive scenario and sensitivity analyses were conducted. RESULTS: Estimated costs were lowest with iGlarLixi (£31,295) compared with iGlar plus Dula (£38,790), iDegLira (£40,179), and BI plus Lira (£42,467). Total QALYs gained were identical with iGlarLixi and iDegLira (8.438), and comparable with iGlar plus Dula (8.439) and BI plus Lira (8.466). NMB for iGlarLixi was positive versus all comparators (£10,603.86 vs. BI plus Lira; £7,466.24 vs. iGlar plus Dula; £8.874.11 vs. iDegLira). CONCLUSION: In patients with T2DM with suboptimal glycemic control on basal insulin, iGlarLixi provides very similar outcomes and substantial cost savings, compared with other fixed and free combinations of insulins plus glucagon-like peptide-1 receptor agonists. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s13300-021-01159-y. |
format | Online Article Text |
id | pubmed-8586275 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer Healthcare |
record_format | MEDLINE/PubMed |
spelling | pubmed-85862752021-11-23 Cost-Effectiveness of iGlarLixi in People with Type 2 Diabetes Mellitus Suboptimally Controlled on Basal Insulin Plus Metformin in the UK McCrimmon, Rory J. Falla, Edel Sha, Jo Zhou Alsaleh, Abdul Jabbar Omar Lew, Elisheva Hudson, Richard Baxter, Mike Palmer, Karen Diabetes Ther Original Research INTRODUCTION: A cost-effectiveness analysis was conducted comparing a fixed-ratio combination (FRC) of insulin glargine 100 units/mL plus lixisenatide (iGlarLixi) versus the FRC of insulin degludec plus liraglutide (iDegLira) and the free-combination comparators insulin glargine plus dulaglutide (iGlar plus Dula) and basal insulin plus liraglutide (BI plus Lira). METHODS: The IQVIA Core Diabetes Model was used to estimate lifetime costs and outcomes for a cohort of patients with type 2 diabetes mellitus (T2DM) from the UK healthcare perspective. Initial clinical data for iGlarLixi were based on the randomized, controlled LixiLan-L trial and the relative treatment effects for comparators were based on an indirect treatment comparison using data from the AWARD-9 (iGlar plus Dula), LIRA ADD2 BASAL (BI plus Lira), and DUAL V (iDegLira) trials. Costs were derived from publicly available sources. Lifetime costs (in British Pound Sterling [£]) and quality-adjusted life-years (QALYs) were predicted; net monetary benefit (NMB) for iGlarLixi versus comparators was derived using a willingness-to-pay threshold of £20,000. Extensive scenario and sensitivity analyses were conducted. RESULTS: Estimated costs were lowest with iGlarLixi (£31,295) compared with iGlar plus Dula (£38,790), iDegLira (£40,179), and BI plus Lira (£42,467). Total QALYs gained were identical with iGlarLixi and iDegLira (8.438), and comparable with iGlar plus Dula (8.439) and BI plus Lira (8.466). NMB for iGlarLixi was positive versus all comparators (£10,603.86 vs. BI plus Lira; £7,466.24 vs. iGlar plus Dula; £8.874.11 vs. iDegLira). CONCLUSION: In patients with T2DM with suboptimal glycemic control on basal insulin, iGlarLixi provides very similar outcomes and substantial cost savings, compared with other fixed and free combinations of insulins plus glucagon-like peptide-1 receptor agonists. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s13300-021-01159-y. Springer Healthcare 2021-10-29 2021-12 /pmc/articles/PMC8586275/ /pubmed/34714523 http://dx.doi.org/10.1007/s13300-021-01159-y Text en © The Author(s) 2021 https://creativecommons.org/licenses/by-nc/4.0/Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Original Research McCrimmon, Rory J. Falla, Edel Sha, Jo Zhou Alsaleh, Abdul Jabbar Omar Lew, Elisheva Hudson, Richard Baxter, Mike Palmer, Karen Cost-Effectiveness of iGlarLixi in People with Type 2 Diabetes Mellitus Suboptimally Controlled on Basal Insulin Plus Metformin in the UK |
title | Cost-Effectiveness of iGlarLixi in People with Type 2 Diabetes Mellitus Suboptimally Controlled on Basal Insulin Plus Metformin in the UK |
title_full | Cost-Effectiveness of iGlarLixi in People with Type 2 Diabetes Mellitus Suboptimally Controlled on Basal Insulin Plus Metformin in the UK |
title_fullStr | Cost-Effectiveness of iGlarLixi in People with Type 2 Diabetes Mellitus Suboptimally Controlled on Basal Insulin Plus Metformin in the UK |
title_full_unstemmed | Cost-Effectiveness of iGlarLixi in People with Type 2 Diabetes Mellitus Suboptimally Controlled on Basal Insulin Plus Metformin in the UK |
title_short | Cost-Effectiveness of iGlarLixi in People with Type 2 Diabetes Mellitus Suboptimally Controlled on Basal Insulin Plus Metformin in the UK |
title_sort | cost-effectiveness of iglarlixi in people with type 2 diabetes mellitus suboptimally controlled on basal insulin plus metformin in the uk |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8586275/ https://www.ncbi.nlm.nih.gov/pubmed/34714523 http://dx.doi.org/10.1007/s13300-021-01159-y |
work_keys_str_mv | AT mccrimmonroryj costeffectivenessofiglarlixiinpeoplewithtype2diabetesmellitussuboptimallycontrolledonbasalinsulinplusmetforminintheuk AT fallaedel costeffectivenessofiglarlixiinpeoplewithtype2diabetesmellitussuboptimallycontrolledonbasalinsulinplusmetforminintheuk AT shajozhou costeffectivenessofiglarlixiinpeoplewithtype2diabetesmellitussuboptimallycontrolledonbasalinsulinplusmetforminintheuk AT alsalehabduljabbaromar costeffectivenessofiglarlixiinpeoplewithtype2diabetesmellitussuboptimallycontrolledonbasalinsulinplusmetforminintheuk AT lewelisheva costeffectivenessofiglarlixiinpeoplewithtype2diabetesmellitussuboptimallycontrolledonbasalinsulinplusmetforminintheuk AT hudsonrichard costeffectivenessofiglarlixiinpeoplewithtype2diabetesmellitussuboptimallycontrolledonbasalinsulinplusmetforminintheuk AT baxtermike costeffectivenessofiglarlixiinpeoplewithtype2diabetesmellitussuboptimallycontrolledonbasalinsulinplusmetforminintheuk AT palmerkaren costeffectivenessofiglarlixiinpeoplewithtype2diabetesmellitussuboptimallycontrolledonbasalinsulinplusmetforminintheuk |